Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

ClinicalTrials.gov ID: NCT06991114

Public ClinicalTrials.gov record NCT06991114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Study identification

NCT ID
NCT06991114
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 8, 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028
Last update posted
Jul 30, 2026

2025 – 2029

United States locations

U.S. sites
31
U.S. states
13
U.S. cities
30
Facility City State ZIP Site status
Artiva Investigational Site Tuscaloosa Tuscaloosa Alabama 35406 Recruiting
Artiva Investigational Site Phoenix Phoenix Arizona 85037 Recruiting
Artiva Investigational Site Tucson Tucson Arizona 85748 Recruiting
Artiva Investigational Site Chula Vista Chula Vista California 92108 Recruiting
Artiva Investigational Site Covina Covina California 91723 Recruiting
Artiva Investigational Site Los Alamitos Los Alamitos California 90720 Recruiting
Artiva Investigational Site Los Angeles Los Angeles California 90027 Recruiting
Artiva Investigational Site Santa Ana Santa Ana California 92706 Recruiting
Artiva Investigational Site Tustin Tustin California 92780 Recruiting
Artiva Investigational Site Jupiter Jupiter Florida 33458 Recruiting
Artiva Investigational Site Miami Miami Florida 33143 Recruiting
Artiva Investigational Site Plantation Plantation Florida 33324 Recruiting
Artiva Investigational Site Gainesville Gainesville Georgia 30501 Recruiting
Artiva Investigational Site Norcross Norcross Georgia 30092 Recruiting
Artiva Investigational Site Willowbrook Willowbrook Illinois 60527 Recruiting
Artiva Investigational Site Iowa Iowa City Iowa 52242 Recruiting
Artiva Investigational Site Iowa Great Falls Great Falls Montana 59405 Recruiting
Artiva Investigational Site Charlotte Charlotte North Carolina 28207 Recruiting
Artiva Investigational Site Charlotte Charlotte North Carolina 28625 Recruiting
Artiva Investigational Site Statesville Statesville North Carolina 27103 Recruiting
Artiva Investigational Site Charleston Charleston South Carolina 29407 Recruiting
Artiva Investigational Site Hixson Hixson Tennessee 37343 Recruiting
Artiva Investigational Site Jackson Jackson Tennessee 38305 Recruiting
Artiva Investigational Site Arlington Arlington Texas 76012 Recruiting
Artiva Investigational Site Bellaire Bellaire Texas 77401 Recruiting
Artiva Investigational Site Irving Irving Texas 75061 Recruiting
Artiva Investigational Site Katy Katy Texas 77494 Recruiting
Artiva Investigational Site Mesquite Mesquite Texas 75150 Recruiting
Artiva Investigational Site Red Oak Red Oak Texas 75154 Recruiting
Artiva Investigational Site Woodland Woodland Texas 77382 Recruiting
Artiva Investigational Site Roanoke Roanoke Virginia 24016 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06991114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06991114 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →